OBJECTIVE: A continuous glucose monitor satisfaction scale (CGM-SAT) was evaluated during a 6-month randomized controlled trial of the GlucoWatch G2 Biographer (GW2B) in youths with type 1 diabetes. RESEARCH DESIGN AND METHODS: At the end of the 6-month trial, 97 parents and 66 older children who had been randomized to the GW2B group completed theCGM-SAT, which assesses satisfaction on 37 items using a five-point Likert scale. Descriptive analysis, calculation of several reliability estimates, and assessment of concurrent validity were performed. RESULTS: The CGM-SAT demonstrated high internal reliability (Cronbach's alpha = 0.95 for parents and 0.94 for youths aged > or = 11 years), split-half reliability (rho = 0.91 for parents and 0.93 for youths), and parent-adolescent agreement (rho = 0.68, P < 0.001). Convergent validity was supported by marginally significant associations with treatment adherence and frequency of GW2B use. CGM-SAT scores did not correlate significantly with changes in treatment adherence, quality of life, or diabetes-related anxiety from baseline to 6 months. Mean scores on CGM-SAT items indicated that 81% of parental responses and 73% of youths' responses were less favorable than "neutral." Descriptive analysis indicated the GW2B requires substantial improvement before it can achieve widespread clinical utility and acceptance. CONCLUSIONS: The results supported the psychometric properties of the CGM-SAT. The CGM-SAT warrants further research use and cross-validation with other continuous glucose monitors. This study provides a benchmark for comparison with new glucose sensors.
RCT Entities:
OBJECTIVE: A continuous glucose monitor satisfaction scale (CGM-SAT) was evaluated during a 6-month randomized controlled trial of the GlucoWatch G2 Biographer (GW2B) in youths with type 1 diabetes. RESEARCH DESIGN AND METHODS: At the end of the 6-month trial, 97 parents and 66 older children who had been randomized to the GW2B group completed the CGM-SAT, which assesses satisfaction on 37 items using a five-point Likert scale. Descriptive analysis, calculation of several reliability estimates, and assessment of concurrent validity were performed. RESULTS: The CGM-SAT demonstrated high internal reliability (Cronbach's alpha = 0.95 for parents and 0.94 for youths aged > or = 11 years), split-half reliability (rho = 0.91 for parents and 0.93 for youths), and parent-adolescent agreement (rho = 0.68, P < 0.001). Convergent validity was supported by marginally significant associations with treatment adherence and frequency of GW2B use. CGM-SAT scores did not correlate significantly with changes in treatment adherence, quality of life, or diabetes-related anxiety from baseline to 6 months. Mean scores on CGM-SAT items indicated that 81% of parental responses and 73% of youths' responses were less favorable than "neutral." Descriptive analysis indicated the GW2B requires substantial improvement before it can achieve widespread clinical utility and acceptance. CONCLUSIONS: The results supported the psychometric properties of the CGM-SAT. The CGM-SAT warrants further research use and cross-validation with other continuous glucose monitors. This study provides a benchmark for comparison with new glucose sensors.
Authors: H Peter Chase; Roy Beck; William Tamborlane; Bruce Buckingham; Nelly Mauras; Eva Tsalikian; Tim Wysocki; Stuart Weinzimer; Craig Kollman; Katrina Ruedy; Dongyuan Xing Journal: Diabetes Care Date: 2005-05 Impact factor: 19.112
Authors: T M Gross; B W Bode; D Einhorn; D M Kayne; J H Reed; N H White; J J Mastrototaro Journal: Diabetes Technol Ther Date: 2000 Impact factor: 6.118
Authors: M A Harris; T Wysocki; M Sadler; K Wilkinson; L M Harvey; L M Buckloh; N Mauras; N H White Journal: Diabetes Care Date: 2000-09 Impact factor: 19.112
Authors: G S Wilson; Y Zhang; G Reach; D Moatti-Sirat; V Poitout; D R Thévenot; F Lemonnier; J C Klein Journal: Clin Chem Date: 1992-09 Impact factor: 8.327
Authors: Bruce Buckingham; Roy W Beck; William V Tamborlane; Dongyuan Xing; Craig Kollman; Rosanna Fiallo-Scharer; Nelly Mauras; Katrina J Ruedy; Michael Tansey; Stuart A Weinzimer; Tim Wysocki Journal: J Pediatr Date: 2007-08-24 Impact factor: 4.406
Authors: Roy W Beck; Jean M Lawrence; Lori Laffel; Tim Wysocki; Dongyuan Xing; Elbert S Huang; Brett Ives; Craig Kollman; Joyce Lee; Katrina J Ruedy; William V Tamborlane Journal: Diabetes Care Date: 2010-08-09 Impact factor: 19.112
Authors: Stuart Weinzimer; Dongyuan Xing; Michael Tansey; Rosanna Fiallo-Scharer; Nelly Mauras; Tim Wysocki; Roy Beck; William Tamborlane; Katrina Ruedy Journal: Diabetes Care Date: 2007-12-20 Impact factor: 19.112